Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zinpentraxin alfa - Roche

Drug Profile

Zinpentraxin alfa - Roche

Alternative Names: PRM-151; recombinant human pentraxin-2 - Roche; RG-6354; rhPentraxin-2; rhPTX 2; rhSAP; RO-7490677

Latest Information Update: 30 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Promedior
  • Developer Roche
  • Class Anti-inflammatories; Antifibrotics; Eye disorder therapies; Glycoproteins; Hepatoprotectants; Recombinant proteins; Urologics
  • Mechanism of Action Protein replacements; Transforming growth factor beta1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scars; Myelofibrosis; Idiopathic pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Myelofibrosis; Scars
  • Phase I Crohn's disease
  • No development reported Kidney disorders; Lung disorders; Non-alcoholic steatohepatitis
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 09 Dec 2023 Zinpentraxin alfa is still in phase II trials for Myelofibrosis in Canada, France, Germany, Israel, Italy, Netherlands, the US and UK
  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 03 Nov 2023 Roche completes a phase I clinical trials in Crohn's disease (In volunteers) in USA (IV) (ISRCTN12950872)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top